Cancer Research Annual Meeting 2010  Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nakashima, T.
Right arrow Articles by Hara, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nakashima, T.
Right arrow Articles by Hara, M.
[Cancer Research 60, 1229-1235, March 1, 2000]
© 2000 American Association for Cancer Research


Biochemistry and Biophysics

Tetrocarcin A Inhibits Mitochondrial Functions of Bcl-2 and Suppresses Its Anti-apoptotic Activity

Takayuki Nakashima, Masayuki Miura and Mitsunobu Hara1

Drug Discovery Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Nagaizumi-cho, Suntou-gun, Shizuoka 411-8731 [T. N., M. H.]; and Department of Neuroanatomy, Biomedical Research Center, Osaka University Medical School, Osaka 565-0871 [M. M.], Japan

Bcl-2 is an integral, intracellular membrane protein that prevents cells from undergoing apoptosis in response to a variety of cell death signals. It negatively regulates the activation of Caspase-3, which functions as effector of mammalian cell death pathways. Overexpression of Bcl-2 inhibits the caspase activities and apoptosis. A microbial secondary metabolite, Tetrocarcin A (TC-A), was identified as an inhibitor of the anti-apoptotic function of Bcl-2. Apoptosis could be induced in cell lines that overexpressed Bcl-2 or Bcl-XL when the cells were treated with anti-Fas antibody, tumor necrosis factor {alpha}, staurosporine, or Bax, in addition to TC-A. TC-A showed selectivity against the pro-apoptotic Bcl-2 family members, in that cells overexpressing CrmA or dominant-negative FADD could not undergo apoptosis with TC-A treatment. In Bcl-2-overexpressing cell lines, TC-A inhibited mitochondrial functions regulated by Bcl-2, resulting in Fas-triggered mitochondrial transmembrane potential loss and cytochrome c release. Inhibition of the mitochondrial functions of Bcl-2 and, thereby, its anti-apoptotic effect could serve as useful pharmacological targets. Thus, TC-A should serve as an archetype for specific inhibitors of Bcl-2 functions.




This article has been cited by other articles:


Home page
Cancer Res.Home page
R. Nakai, S.-i. Iida, T. Takahashi, T. Tsujita, S. Okamoto, C. Takada, K. Akasaka, S. Ichikawa, H. Ishida, H. Kusaka, et al.
K858, a Novel Inhibitor of Mitotic Kinesin Eg5 and Antitumor Agent, Induces Cell Death in Cancer Cells
Cancer Res., May 1, 2009; 69(9): 3901 - 3909.
[Abstract] [Full Text] [PDF]


Home page
J. Bacteriol.Home page
J. Fang, Y. Zhang, L. Huang, X. Jia, Q. Zhang, X. Zhang, G. Tang, and W. Liu
Cloning and Characterization of the Tetrocarcin A Gene Cluster from Micromonospora chalcea NRRL 11289 Reveals a Highly Conserved Strategy for Tetronate Biosynthesis in Spirotetronate Antibiotics
J. Bacteriol., September 1, 2008; 190(17): 6014 - 6025.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. Kroemer, L. Galluzzi, and C. Brenner
Mitochondrial Membrane Permeabilization in Cell Death
Physiol Rev, January 1, 2007; 87(1): 99 - 163.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
U. Fischer and K. Schulze-Osthoff
New Approaches and Therapeutics Targeting Apoptosis in Disease
Pharmacol. Rev., June 1, 2005; 57(2): 187 - 215.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
C. L. Oliver, M. B. Miranda, S. Shangary, S. Land, S. Wang, and D. E. Johnson
(-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-XL-mediated apoptosis resistance
Mol. Cancer Ther., January 1, 2005; 4(1): 23 - 31.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
G. Z. Rassidakis, L. J. Medeiros, T. P. Vassilakopoulos, S. Viviani, V. Bonfante, G. Nadali, M. Herling, M. K. Angelopoulou, R. Giardini, M. Chilosi, et al.
BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens
Blood, December 1, 2002; 100(12): 3935 - 3941.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. M. Dirsch, H. Stuppner, and A. M. Vollmar
Helenalin Triggers a CD95 Death Receptor-independent Apoptosis That Is Not Affected by Overexpression of Bcl-xL or Bcl-2
Cancer Res., August 1, 2001; 61(15): 5817 - 5823.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.